Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Comparative analysis of surgical interventions for osteonecrosis of the femoral head: a network meta-analysis of randomized controlled trials

References

Year

Country

Design

Treatment

Mean age(years)

Case(hip)

Inclusion criteria

Follow-up (months)

Outcomes

Jayankura et al. [10]

2023

Belgium

RCT

OB

46

23

ARCO I–II

24

Progress, THA

    

CD

45

26

   

Wan et al. [9]

2022

China

RCT

FFG

29.8

45

ARCO II

36

HHS, progress, THA

    

VBG

28.8

46

   
    

ABG

30.5

45

   
    

BMG

30.5

46

   

Zhang et al. [19]

2022

China

RCT

FFG

34.3

29

ARCO II

24

HHS, progress, THA

    

VBG

34.4

30

   

Park et al. [12]

2022

Korea

RCT

BMG

49.3

10

Ficat I–II

36

HHS, progress, THA

    

CD

55.6

10

   

Aggarwal et al. [18]

2021

India

RCT

PRP

35.2

25

ARCO I–II

12

Progress, THA

    

CD

38.2

28

   

Li et al. [7]

2021

China

RCT

BMAC

35.4

22

Ficat I–IV

24

HHS, progress, THA

    

BMG

39.4

29

   

Li et al. [22]

2020

China

RCT

ABG

38.2

20

Ficat II–III

24

Progress, THA

    

BMAC + ABG

34.1

21

   

Hauzeur et al. [8]

2020

Belgium

RCT

BMAC

50

26

ARCO I–II

36

Progress, THA

    

OB

51

27

   

Hu et al. [4]

2018

China

RCT

CD

40.3

65

ARCO I–II

24

HHS, progress

    

FFG

40.8

65

   

Lin et al. [17]

2018

China

RCT

BMG

31.5

16

ARCO II–III

36

HHS, progress, THA

    

ABG

32.6

16

   

Cao et al. [20]

2017

China

RCT

VBG

31

27

ARCO I–III

36

HHS, progress, THA

    

CD

 

27

   

Li et al. [21]

2016

China

RCT

ABG

36.5

23

Ficat I–II

24

HHS, progress, THA

    

VBG

 

24

   

Zhao et al. [23]

2016

China

RCT

ABG

33

25

ARCO II–III

12

HHS, progress

    

BMG + VBG

30

23

   

Pepke et al. [11]

2016

Germany

RCT

BMAC

44.5

14

ARCO II

24

HHS, progress, THA

    

CD

44.3

11

   

Tabatabaee et al. [24]

2015

Iran

RCT

BMAC

29.1

14

ARCO I–III

24

Progress, THA

    

CD

 

14

   

Mao et al. [13]

2015

China

RCT

BMAC: + BMG

34.6

48

ARCO I–III

36

HHS, progress, THA

    

BMG

36.1

41

   

Ma et al. [5]

2014

China

RCT

ABG

34.8

24

Ficat I–III

24

Progress, THA

    

BMAC + ABG

35.6

25

   

Zhao et al. [14]

2012

China

RCT

CD

33.8

44

ARCO I–II

24

HHS, progress, THA

    

BMAC

32.7

53

   
  1. ABG autologous iliac bone grafting, ABG + BMAC autologous bone grafting and bone marrow aspirate concentrate, BMAC bone marrow aspirate concentration, BMG biomaterials grafting, BMG + BMAC biomaterials grafting and bone marrow aspirate concentration, CI confidence interval, CD core decompression, FFG free fibular graft, HHS Harris hip score, MD mean difference, NMA network meta-analysis, OR odds ratio, ONFH osteonecrosis of the femoral head, OB osteoblastic cells, PRP platelet-rich plasma, RCT randomized controlled trial, THA total hip arthroplasty, VBG vascularized bone grafting, VBG + BMG vascularized bone grafting combined with biomaterial